Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AGIO |
---|---|---|
09:32 ET | 112061 | 47.18 |
09:34 ET | 200 | 47.14 |
09:45 ET | 500 | 47.46 |
09:50 ET | 500 | 47.22 |
09:52 ET | 570 | 47.135 |
09:56 ET | 400 | 47.11 |
09:59 ET | 600 | 47.35 |
10:01 ET | 1131 | 47.455 |
10:14 ET | 800 | 47.29 |
10:15 ET | 243 | 47.32 |
10:17 ET | 200 | 47.36 |
10:19 ET | 1296 | 47.385 |
10:21 ET | 300 | 47.4 |
10:28 ET | 2100 | 47.5 |
10:30 ET | 100 | 47.52 |
10:32 ET | 100 | 47.51 |
10:33 ET | 147 | 47.489 |
10:37 ET | 1700 | 47.43 |
10:39 ET | 100 | 47.46 |
10:44 ET | 600 | 47.45 |
10:46 ET | 600 | 47.47 |
10:51 ET | 300 | 47.41 |
10:55 ET | 700 | 47.435 |
10:57 ET | 200 | 47.48 |
11:02 ET | 300 | 47.36 |
11:04 ET | 1755 | 47.365 |
11:06 ET | 900 | 47.25 |
11:08 ET | 100 | 47.27 |
11:11 ET | 500 | 47.1 |
11:24 ET | 200 | 47 |
11:29 ET | 13591 | 46.81 |
11:33 ET | 1100 | 46.52 |
11:36 ET | 899 | 46.64 |
11:38 ET | 100 | 46.75 |
11:40 ET | 200 | 46.765 |
11:44 ET | 652 | 46.79 |
11:45 ET | 300 | 46.77 |
11:47 ET | 100 | 46.72 |
11:51 ET | 236 | 46.61 |
11:54 ET | 100 | 46.58 |
12:09 ET | 600 | 46.69 |
12:12 ET | 200 | 46.72 |
12:20 ET | 300 | 46.7 |
12:21 ET | 100 | 46.74 |
12:25 ET | 1100 | 46.76 |
12:27 ET | 600 | 46.7 |
12:30 ET | 300 | 46.65 |
12:32 ET | 600 | 46.63 |
12:38 ET | 1100 | 46.71 |
12:41 ET | 100 | 46.79 |
12:50 ET | 700 | 46.81 |
12:54 ET | 100 | 46.95 |
12:57 ET | 500 | 46.82 |
12:59 ET | 100 | 46.91 |
01:03 ET | 100 | 46.92 |
01:06 ET | 400 | 46.72 |
01:08 ET | 300 | 46.81 |
01:10 ET | 300 | 46.87 |
01:14 ET | 200 | 46.91 |
01:15 ET | 600 | 46.94 |
01:19 ET | 400 | 46.91 |
01:21 ET | 1280 | 46.89 |
01:24 ET | 844 | 46.814 |
01:26 ET | 100 | 46.83 |
01:28 ET | 100 | 46.8 |
01:30 ET | 700 | 46.79 |
01:32 ET | 1984 | 46.84 |
01:33 ET | 700 | 46.89 |
01:35 ET | 1000 | 46.96 |
01:37 ET | 100 | 46.96 |
01:39 ET | 200 | 47.01 |
01:42 ET | 100 | 47 |
01:44 ET | 100 | 47.05 |
01:48 ET | 300 | 46.95 |
01:50 ET | 355 | 46.97 |
01:51 ET | 200 | 46.99 |
01:57 ET | 400 | 46.93 |
02:00 ET | 100 | 46.9 |
02:04 ET | 200 | 46.9 |
02:06 ET | 450 | 46.86 |
02:08 ET | 200 | 46.78 |
02:09 ET | 200 | 46.8 |
02:11 ET | 400 | 46.78 |
02:13 ET | 2234 | 46.85 |
02:15 ET | 300 | 46.95 |
02:18 ET | 200 | 46.88 |
02:24 ET | 300 | 46.93 |
02:27 ET | 600 | 46.88 |
02:31 ET | 400 | 46.87 |
02:36 ET | 100 | 46.855 |
02:38 ET | 600 | 46.91 |
02:40 ET | 1300 | 46.93 |
02:42 ET | 900 | 46.95 |
02:44 ET | 100 | 46.91 |
02:45 ET | 400 | 47.01 |
02:47 ET | 400 | 47.04 |
02:51 ET | 1287 | 47.13 |
02:54 ET | 100 | 47.13 |
02:58 ET | 200 | 47.095 |
03:00 ET | 1200 | 47.07 |
03:02 ET | 100 | 47.075 |
03:03 ET | 1100 | 47.03 |
03:05 ET | 891 | 46.97 |
03:07 ET | 849 | 47.01 |
03:09 ET | 500 | 46.975 |
03:12 ET | 3066 | 47.02 |
03:14 ET | 605 | 47.04 |
03:16 ET | 1300 | 47.03 |
03:18 ET | 1880 | 47.03 |
03:20 ET | 300 | 47.04 |
03:21 ET | 2415 | 47.035 |
03:23 ET | 13778 | 47.17 |
03:25 ET | 1300 | 47.06 |
03:27 ET | 1200 | 47.24 |
03:32 ET | 200 | 47.185 |
03:34 ET | 3252 | 47.14 |
03:36 ET | 1100 | 47.18 |
03:38 ET | 300 | 47.105 |
03:39 ET | 2200 | 47.18 |
03:41 ET | 1844 | 47.16 |
03:43 ET | 886 | 47.09 |
03:45 ET | 1600 | 47.095 |
03:48 ET | 2390 | 47.1 |
03:50 ET | 806 | 47.12 |
03:52 ET | 3921 | 47.025 |
03:54 ET | 6412 | 47.08 |
03:56 ET | 8395 | 46.75 |
03:57 ET | 19296 | 46.81 |
03:59 ET | 558300 | 46.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Agios Pharmaceuticals Inc | 2.6B | -7.2x | --- |
Janux Therapeutics Inc | 2.6B | -54.9x | --- |
Edgewise Therapeutics Inc | 2.7B | -18.4x | --- |
CG Oncology Inc | 2.6B | -33.4x | --- |
Celldex Therapeutics Inc | 2.7B | -15.0x | --- |
SpringWorks Therapeutics Inc | 2.6B | -7.7x | --- |
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $31.3M |
Shares Outstanding | 56.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-6.49 |
Book Value | $14.50 |
P/E Ratio | -7.2x |
Price/Sales (TTM) | 84.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,293.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.